STUDresearch · Peptide

Epitalon

Also known as

Epithalon · Epithalone · AEDG · AEDG peptide · Ala-Glu-Asp-Gly · AlaGluAspGly · Epithalamin (related pineal extract; not identical) · Epithalamine (spelling variant of the extract) · Khavinson pineal tetrapeptide · CAS 307297-39-8

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗

Peptide Lots of talk Systemic Subcutaneous; other forms discussed separately Longevity & bioregulators

Systemic — pineal/telomere longevity peptide; not a local injury-site agent.

What people say Epitalon is a synthetic four-amino-acid peptide discussed for sleep and longevity. Its telomere and pineal stories come from different kinds of evidence; it is not the same substance as epithalamin extract. Doses people talk about

Microgram hypothesis100–500 mcg/day

Contested synthetic-peptide hypothesis based partly on animal translation; route/form varies between discussions, not established human dosing.

Lower milligram charts1–2 mg/day

Subcutaneous community charts generally discuss longer blocks than higher-milligram courses; not a verified safe starting range.

Short-course commercial charts5–10 mg subcutaneous per day (same milligram as epithalamin extract charts)

Historical epithalamin extract IM courses used this milligram band. Clinic and vendor pages still list it for synthetic Epitalon. Critics call that a copy-across; it remains the loud commercial pattern, not a proven AEDG equivalent.

These figures describe competing discussion patterns, not equivalent exposures or recommendations. Epitalon is not epithalamin extract. Route, units and product identity matter.

Half-life & effect duration

Half-life in the body: Half-lifeNo settled estimate
Felt duration people report: Positive post-course accountBetter sleep 3 days later, fading within weeks
Other accountDisrupted sleep for 3 days after stopping

Timing context & sources

How it may feel People describe easier sleep, vivid dreams, subtle changes or no obvious effect. Some instead feel wired or sleep worse. A change in sleep does not establish a longevity benefit.

Cycles people discuss Short ten-to-twenty-day courses with gaps of several months are prominent in community discussion; monthly microgram calendars are a different, contested pattern. Neither proves durable benefit. Timing Evening use follows the sleep-related framing, but some posters describe worse sleep with night use. Course timing is community practice, not a calculation from a verified half-life. Stacks Classic pair — Epitalon + Thymalin: “Soviet / Khavinson longevity” stack: pineal tetrapeptide + thymic complex; concurrent 10–20 day courses or separate annual courses. Access talk April 2026 Category 2 off: Coming off the do-not-compound bucket is not Category 1, not 503A placement, and not approval. Labs people mention No Epitalon blood level: Sleep/dream notes during the course are the in-block log. Watch for Telomerase / cancer theory: Theoretical caution because many cancers upregulate telomerase; community and clinic talk often excludes active malignancy or high-risk history pending medical review.

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

A measured human half-life is not established by the sources checked. Neither a minutes estimate nor an hours estimate is verified here.

The FDA review describes a preliminary labelled-peptide experiment in rabbits, not a human clearance study.

PDF viewer page 30 (printed page 29) was read and visually inspected. Tissue fluorescence at one hour was not shown to be specific to intact Epitalon; FDA identified no additional PK studies at that evaluation. The underlying rabbit report was not independently read. This does not prove that no later study exists.

FDA Epitalon briefing: pharmacokinetic evidence limitations (opens in a new tab)Printed page 29 / PDF viewer page 30, Pharmacokinetics/Toxicokinetics: preliminary pregnant-rabbit IV fluorescence study and limits on identifying intact peptide; no additional PK studies identified at evaluation.Official literature evaluation, not a new experiment. Relevant complete page inspected; underlying rabbit full report not read. No current legal-status conclusion is inferred.

Felt duration people report

One user reports better sleep three days after a course, then says it faded within weeks. Another reports disrupted sleep for three days after stopping.

These are post-course experiences, not proof of a lasting reset or a per-dose effect window.

The positive poster also used retatrutide and later switched to a mixed tablet, which is excluded from Epitalon-only attribution. The adverse account includes an accidental larger exposure; a reply alleges it is a repeated post, so it is counted once. Unverified products and uncontrolled reports cannot establish causality or frequency.

Epitalon sleep account with later follow-up (opens in a new tab)Proud-Ability-4187: three days after finishing course, then reply that Epitalon stopped working a few weeks after the cycle; later mixed SleepEQ product discussed separately.Retatrutide co-use, severe prior sleep difficulty and unverified product. Follow-up contradicts a permanent-reset reading of the initial enthusiastic post; no cure claim or protocol adopted. The dose reply is ambiguous between daily and course amount; this review does not resolve it.
Epitalon experience: disrupted sleep after stopping (opens in a new tab)MissLov12345 original post: fragmented sleep during use and three days of sleep difficulty after the final exposure; accidental amount mix-up disclosed.One uncontrolled report; route unspecified. Comment alleges a repeated post, not independent corroboration. The poster's melatonin mechanism guess and retry advice are not adopted.

Other context in this card

Epitalon: distinct identity and nominated concentrations (opens in a new tab)FDA Epitalon briefing: introductory footnote 6 identity distinction; printed page 21 commercial charts; nominated SC concentrations; Pharmacokinetics/Toxicokinetics printed page 29, PDF viewer page 30. Actual independent text review September 6.Different from epithalamin; concentrations and commercial charts are not validated human doses. No current legal conclusion follows from this briefing.
PCAC: insomnia scope and advisory status (opens in a new tab)Official agenda lists Epitalon for insomnia; advisory-committee explanation says recommendations are non-binding. Actual acting-AI page inspection September 6.Official agenda, not an official vote transcript or drug approval.
PCAC Epitalon vote: secondary report (opens in a new tab)What Happened at the Meeting and Results, vote table: Epitalon 7–4–1, free base and acetate. Actual acting-AI content inspection September 6; this is secondary reporting, not official minutes.The legal commentary incorrectly describes the agenda’s Epitalon use elsewhere; only its explicitly labeled vote table is used. Official agenda controls the insomnia scope.
FDA: separate bulks-list process (opens in a new tab)Developing the 503A Bulks List: evaluation and notice-and-comment rulemaking; distinct interim-policy categories. Actual acting-AI content inspection September 6.Process explanation, not certification of current product access or every jurisdiction.

What people say 16

Telomere logs (humans): Some multi-course users chase telomere assays or “biological age” kits; results uneven, uncontrolled, assay-noisy, and confounded by stacks/lifestyle. anecdote
Sleep quality: Night dosers commonly report easier onset, deeper rest, more memorable/vivid dreams, and sometimes better morning energy during a course. forum
Timeline note (community sleep): Some writeups place the first clear sleep/dream shift around nights ~2–5 of a course rather than day one. forum
Subjective vitality: Multi-course logs sometimes note subtle energy, recovery continuity, or “quieter aging” — heavily confounded by stacks, sleep hygiene, and expectancy. anecdote
vs TA-65: Injectable research-peptide alternative to oral cycloastragenol-class telomerase products; no head-to-head human trials. forum
Telomeres (cells): Human fetal fibroblast work (widely cited Khavinson lineage, e.g. ~2003) reports telomerase induction, longer telomeres, and divisions past the Hayflick limit — cell-culture signal, not proven clinical life extension. lab
Non-monotonic cell signal (recent): In-vitro telomere-length work in at least one breast-cancer cell line (BT474) is cited for peak elongation around ~0.2 µg/mL with declining effect at higher concentrations — used in the microgram-hypothesis literature to argue “more mg ≠ better.” lab
Melatonin / pineal (humans, extract): Epithalamin reports of restored nocturnal melatonin rhythm in elderly with pineal dysfunction — often cited as the sleep/circadian rationale for synthetic courses. trial
Melatonin (primates, synthetic): Aged rhesus work reports Epitalon restoring evening melatonin and related endocrine markers at microgram-scale animal doses (~10 µg/animal/day) vs much higher epithalamin mg (~5 mg/animal/day) on similar endpoints. animal
Sublingual melatonin metabolite signal: Small night-shift women study (sublingual ~0.5 mg/day × ~20 days) reported higher urinary 6-sulfatoxymelatonin and subjective well-being vs placebo — limited design, not a longevity RCT. trial
Animal lifespan / geroprotection: Fly, mouse, and rat lifespan or healthspan papers from the originator lineage are widely shared; independent Western replication is limited. animal
Murine microgram anchor: Longevity/geroprotection mouse schedules often used absolute microgram-scale Epitalon (e.g. ~1.0 µg/mouse SC on ~5 consecutive days each month long-term; other models ~0.1 µg-class low-dose schedules) — central to allometric “human mcg not mg” arguments. animal
Mortality cohorts (extract): Older Russian epithalamin (± thymalin) trials in elderly/cardiovascular cohorts report lower mortality signals over multi-year follow-up — not independently confirmed Western RCTs of pure Epitalon alone. trial
Antioxidant / DNA damage: Reduced DNA-damage markers in senescence-accelerated mice and improved antioxidant enzyme talk in rodents; comparative fly work is cited claiming Epitalon antioxidant activity at doses ~1,000× lower than epithalamin. animal
Cancer-model nuance (preclinical): Some rodent/cancer-prone models report lower spontaneous tumor incidence, delayed mammary tumors, fewer metastases, or leukemia reduction with epitalon — does not resolve the telomerase–malignancy theoretical debate in humans. animal
What it is not proven for: No high-quality Western evidence that it prevents dementia, extends human lifespan, treats cancer, or produces durable telomere gains on clinical assays. trial

Doses people talk about 23

Identity first (the central debate): Community critics argue that viral “5–10 mg daily” charts recycle epithalamin-extract clinical bands. Synthetic AEDG is a different product; mg/mcg and extract/synthetic mix-ups remain central to the debate. The identity distinction does not prove that every multi-milligram chart arose from the same error. forumtrial
Classic high short course (dominant gray-market / clinic charts): ~5–10 mg subcutaneous daily × ~10 consecutive days (often ~50–100 mg total per course). forum
High 10-day night protocol (clinic template): Fixed ~10 mg once nightly × 10 days then ~4 months off — common commercial/clinic writeup (some specify ~100 mg course total using large vials, e.g. 2×50 mg). forum
Split high daily: ~5 mg AM + ~5 mg PM (or “5–10 mg/day divided BID”) × ~10–20 days in “enhanced” / clinic-style writeups (~100 mg course at 5+5 × 10). forum
Widely cited “standard community” chart: ~2 mg subcutaneous daily (often PM) × ~20 consecutive days (~40 mg total), repeated ~3×/year (~every ~4 months). Many guides call this the most-documented community template. forum
Lower daily band: ~1–2 mg/day for ~15–20 (sometimes up to ~30) days in conservative community charts; some consumer writeups list ~1 mg/injection as a “standard” starter. forum
Broader real-world span (summarized in dosing-critique literature): Community/clinic practice is described as spanning low (~1–2 mg/day, sometimes longer 20–30 day blocks), moderate (~5 mg/day or 5 mg BID, 10–20 days — most-cited), high (~10 mg once or twice daily), and largely anecdotal experimental ≥20 mg/day — still without formal human dose-finding. forum
Microdose / “translational correction” band (contested but loud): Protocol writers and a 2026 mini-review (“microgram hypothesis”) argue synthetic Epitalon may belong in ~100–500 mcg/day (sometimes framed ~100–300 µg per treatment day), not multi-mg — because mg charts came from crude-extract logic and comparative potency data. forum
Anela-style pulsed micro: ~10 days on / ~20 days off at microgram-scale daily targets (often discussed ~100–500 mcg), intended as a monthly rhythm rather than 2–3×/year megadoses. forum
Intermittent high-day schedule (minority): Some guides list ~10 mg on days 1, 5, 9, 13, and 17 of a ~17-day window (not consecutive daily). forum
Five-days-per-week minority: Occasional consumer writeups describe ~1 mg SC five days/week with cycling (e.g. ~1 month on / ~3 months off, ~3 cycles/year) — less common than consecutive 10–20 day bursts. forum
Oral capsules (commerce debate): Community protocol tables sometimes list ~5–10 mg oral once daily × ~10–30 days; enzymatic gut degradation and poor oral bioavailability are the standard counterarguments for a linear tetrapeptide. forum
Intranasal community: Roughly ~100–200 mcg per nostril discussed as ease-of-use; other community tables list ~1–5 mg/day intranasal for 10–20 days for “CNS/pineal access” talk — SC/IM equivalence unproven either way. forum
Timing: Pre-bed / evening most common for pineal–sleep story (often ~30–60 min before bed; some clinic charts say 2+ hours post-meal); morning if night dosing feels wired or alert. Microdose writers often say day vs night matters less than personal sleep response. forum
Course totals people track: Roughly ~40 mg (2 mg × 20), ~50–100 mg (5–10 mg × 10), ~100 mg (5 mg × 20 or 5+5 × 10), or microgram-calendar totals orders of magnitude lower depending on chart family. forum
Self-report culture note: Anonymized community log aggregators often show median/self-report buckets clustering at multi-mg (≥2 mg) even while microdose threads argue those same users are overdosing extract logic. forum
Yearly pattern: ~1–3 (sometimes ~3–4) short courses/year with multi-month gaps, or monthly on/off microdose calendars — continuous open-ended daily use is uncommon in bioregulator culture. forum
Ultra-high clinic marketing outliers: Occasional longevity-clinic pages list ~10–20 mg SQ daily for 10–20 days, 2–3×/year — above the more common 2–10 mg chart families; still research-chem/clinic marketing, not a labeled drug schedule. forum
Primate potency differential (not a human recipe): Aged macaque comparisons used Epitalon ~10 µg/animal/day vs epithalamin ~5 mg/animal/day for melatonin endpoints (~500-fold order-of-magnitude gap) — core citation for “synthetic needs far less.” Direct linear analogy floated in discussion sometimes maps human epithalamin 5–10 mg/day → rough ~10–20 µg Epitalon/day (hypothesis-level, not validated). animal
Sublingual research-style: ~0.5 mg/day × ~20 days appears in a small circadian/melatonin human writeup; bioavailability vs injection not established. trial
Epithalamin clinical bands (do not copy blindly to synthetic vials): Historical IM ~5–10 mg/day × ~10–20 days, or multi-injection 10 mg IM every few days; intranasal epithalamin often ~10–30 mg/day × ~20–30 days in older schedules; multi-year pauses of ~4–6 months between rounds. trial
Framing: Community, clinic-marketing, and literature-discussion ranges only — not advice, not prescriptions, not FDA-labeled dosing. No formal modern human dose-finding package for synthetic Epitalon is the standard reference. forum
Allometric HED cited in microgram hypothesis: Effective murine ~1.0 µg/mouse SC on ~5 consecutive days/month scaled (FDA BSA method) to roughly ~190–230 µg per treatment day for a ~70 kg human — used as a provisional research-range argument, not a proven clinical dose. animal

How it may feel 8

Days 1–3: Little systemic change for many; night-dosers sometimes note slightly easier sleep onset or first vivid-dream nights. forum
Nights ~2–5 (common responder window): Writeups often cluster deeper sleep, dream intensity, and calmer-evening notes here — not stimulant-like. forum
Days 4–10: Common window for sleep-quality or dream-intensity notes if they appear at all. forum
End of 10–20 day course: Deeper rest/recovery narrative for responders; a large minority reports “subtle / nothing obvious” especially when stacked and expectations are longevity-only. forum
Days–weeks post-course: Claimed sleep or vitality steadiness may outlast daily injections; hard to separate from course expectancy and concurrent lifestyle changes. anecdote
Weeks 2–8 post: Longevity users wait on sleep/vitality settle and optional lab curiosity (sleep metrics, telomere kits), not an acute “on-drug” buzz. forum
Months 3–6: Re-run talk on ~2–4× yearly calendar (or monthly pulsed microdose schedules) rather than continuous daily. forum
Multi-year logs: Anecdotal; telomere lab changes and “biological age” claims remain uneven and uncontrolled. anecdote

Around the dose 5

Clock: Night courses are the classic pattern (short blocks, not forever-daily). forum
Sleep: People treat it as a circadian/pineal-adjacent night peptide, not a gym pin. forum
Sleep context: Posters track sleep hours during a course; changes in routine also affect the reported sleep outcome. forum
Ten-day blocks and calendars: Older charts/posts describe short night blocks followed by months off, including “10-day stint × 10 mg” language. One inspected poster described injection “10mg for 10 days” without resolving daily-versus-course amount, then reported that sleep benefit faded within weeks. These are separate accounts, not a repeat-course rule. forum
If night feels wired: Same as older charts — some move the pin earlier. A 503A insomnia vote does not change that personal split. forum

Cycles people discuss 11

Most common consecutive block: ~10 days daily (especially at 5–10 mg charts and clinic 10 mg night templates). forum
Alternate consecutive length: ~15–20 day blocks at ~1–5 mg/day (2 mg × 20 is the “standard community” poster child). forum
Classic off-period: ~4–6 months between courses (~2×/year), or ~every 3–4 months (~3–4×/year); 2 mg × 20 × 3/year is a repeatedly recycled calendar. forum
Monthly pulsed minority: e.g. ~10 days on / ~20 days off repeated year-round at lower/microgram daily targets (Anela-style and similar). forum
1 month on / 3 months off minority: Appears in some consumer writeups (often with lower per-injection targets) totaling ~3 cycles/year. forum
Not continuous daily forever: Bioregulator culture and originator practice favor short bursts with long gaps, not open-ended daily injection. forum
Stack-course alignment: Often run the same calendar window as Thymalin (concurrent days or separate annual immune vs pineal courses). forum
Re-runs: Calendar-based or after sleep/aging goals drift; multi-decade gray-market safety databases do not exist. forum
Judge horizon: Sleep/dream notes within the course; longevity/telomere claims judged across months–years if at all. forum
Still the 2025–26 buy: X/Reddit logs in 2026 still name a 10-day block (often ~5–10 mg/night, sometimes 10 mg × 10) as the course people actually finish, next to a quieter 2 mg × 20 days camp and a microgram-hypothesis camp. forum
Mouse-schedule echo (not a human protocol): Originator-line murine geroprotection often used short multi-day bursts each month for life — cited by microdose calendars more than by multi-mg clinic charts. animal

Timing 7

Forum half-life talk: Informal “a few hours circulating” or “very short / minutes” estimates both appear — neither replaces a measured package. forum
Why short courses anyway: Bioregulator practice history and claimed gene-expression / telomerase / pineal “programming” narratives drive 10–20 day bursts (or monthly micro-pulses) more than depot PK math. forum
After the course: Claimed sleep/melatonin/vitality effects are often described as lasting days–weeks past the last injection. anecdote
Night dosing logic: Evening timing targets the pineal/melatonin story even when acute plasma presence is short. forum
PK honesty: No formal published human pharmacokinetic study reporting measured plasma half-life, clearance, volume of distribution, or absolute bioavailability for synthetic Epitalon is the standard reference — dosing culture is not PK-driven. trial
Structural expectation: Small linear unprotected tetrapeptide → rapid peptidase breakdown and short systemic presence expected (secondary sources sometimes say minutes-class circulating estimates — extrapolations, not measured clinical PK). trial
Oral / sublingual / nasal: Presumed lower or highly variable systemic exposure vs subcutaneous; no published bioequivalence package tying routes to the same mg chart. Gut enzymatic degradation is the main oral-skepticism argument. trial

Stacks 14

Classic pair — Epitalon + Thymalin: “Soviet / Khavinson longevity” stack: pineal tetrapeptide + thymic complex; concurrent 10–20 day courses or separate annual courses. forum
Thymalin concurrent numbers (as discussed): Thymalin often ~5–10 mg daily IM/SubQ during a short ~5–10 (sometimes 10–20) day block; clinic pages sometimes list Thymalin ~10 mg daily × 10 days, repeat ~every 6 months. forum
Timing split within the pair: Some run morning Thymalin / evening Epitalon so pineal dosing stays nocturnal. forum
Other Khavinson shorts: Pinealon, Cartalax, Vesugen, Vilon, Cortagen, Livagen, Ovagen, Testagen, and other cytogen-style bioregulators in multi-organ yearly plans. forum
Sleep side-stack: DSIP, low-dose melatonin, magnesium, and sleep-hygiene work — attribution to Epitalon alone becomes noisy. forum
Mito longevity neighbors: MOTS-c, humanin-class, SS-31 — popular “cell energy + telomere” boards; highly confounded. Example community pairing language: Epitalon PM course + SS-31 or MOTS-c ongoing. forum
Skin / repair adjacency: GHK-Cu (community anti-aging charts sometimes list AM GHK-Cu ~1–2 mg-class talk + PM Epitalon ~2 mg during the course window). forum
GH-axis lifestyle stacks: CJC-1295/Ipamorelin, sermorelin, or MK-677 overlapping a course — sleep and recovery credit is shared. forum
Healing-peptide overlap (minority charts): Some vendor “enhanced recovery” writeups keep Epitalon 5–10 mg daily while adding BPC-157 and/or TB-500 — different primary goals; confounds sleep and recovery logs. forum
Oral telomerase class comparison: Some alternate or sequence TA-65 / cycloastragenol months with Epitalon injection courses; no stack RCT. forum
mTOR / metabolic neighbors: Rapamycin, metformin, NMN/NR talk appears next to Epitalon on longevity forums without clean interaction data. forum
Thymosin Alpha-1 adjacency: Immune-longevity boards sometimes run TA-1 on a different weekly cadence while Epitalon stays in short annual bursts — not a fixed ratio stack. forum
Stack caution: More peptides ≠ clearer signal; injection burden, purity risk, cost, and sleep-attribution noise climb fast on multi-bioregulator calendars. forum
Thymalin cadence note: Originator-adjacent literature sometimes gave the two as separate yearly courses rather than a single mixed vial — community practice varies; they are not the same peptide. trial

Access talk 6

April 2026 Category 2 off: Coming off the do-not-compound bucket is not Category 1, not 503A placement, and not approval. trialforum
How people still get it: Gray-market lyophilized vials and clinic 10-day courses remain the 2026 buy talk until any rule actually lands. forum
July 24, 2026 PCAC: Secondary reports describe a favorable recommendation for free base and acetate. LumaLex’s vote table records 7 yes, 4 no and 1 abstention; older same-day 7–5 reporting remains a historical tally discrepancy, not a second official outcome. FDA’s agenda lists insomnia, not anti-aging; the recommendation is advisory. trial
FDA staff said no: Briefing documents proposed that Epitalon free base and acetate NOT be included, citing thin characterization and no registered Western clinical package for the nominated use. The vote ran against that staff advice. trial
Nominated products in the packet: FDA evaluated proposed subcutaneous products at 10 mg/mL and 3000 mcg/mL. Those are concentrations, not administered amounts or evidence for a particular course calendar. trial
Not a final rule: A PCAC recommendation does not itself add Epitalon to the 503A bulks list or grant FDA drug approval. FDA describes a separate evaluation and notice-and-comment process. This September 6, 2026 review does not certify every jurisdiction’s current access or compounding eligibility. trial

Labs people mention 3

No Epitalon blood level: Sleep/dream notes during the course are the in-block log. forum
Telomere / ‘biological age’ kits: Multi-course users still chase them; 2026 careful threads call the assays noisy and uncontrolled. anecdoteforum
Not a hormone panel peptide: People do not titrate it off IGF-1 or testosterone the way they do GH-axis shots. forum

Storage notes 2

No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Related 8

Watch for 18

Injection-site reports: Redness, sting, itch and irritation appear in multi-milligram or repeated-site accounts. Community notes discuss abdomen/thigh/flank rotation and 29–31G needles; these reports do not establish a safe preparation or explain every reaction. forum
Vivid dreams: Frequently reported during active courses; usually framed as pineal/REM-related rather than harmful. forum
Sleepiness / drowsiness: Some evening dosers feel heavier sleep drive; others feel fine. forum
Mild headache: Occasional early-course headache that often fades. forum
Transient fatigue: Mild tiredness in a minority during the first days. forum
Night mismatch / wired: Some report greater alertness at night and moving use to morning; others describe disrupted sleep timing with morning use too. anecdote
Increased appetite (rare): Minority logs mention appetite uptick; not a dominant side narrative. forum
GI (oral/sublingual products): Occasional digestive discomfort when non-injectable forms are used. forum
Telomerase / cancer theory: Theoretical caution because many cancers upregulate telomerase; community and clinic talk often excludes active malignancy or high-risk history pending medical review. forum
Dose identity mix-up: Copying epithalamin extract mg charts onto synthetic AEDG vials (or the reverse) is a primary self-experiment failure mode; microdose advocates call multi-mg “systematic overdosing,” while multi-mg clinic charts still dominate sales templates. forum
Source quality: Gray-market contamination, underdosed/overdosed labels, wrong peptide in the vial, and missing COAs. forum
Pregnancy / pediatric / breastfeeding: Not a researched use case in community longevity protocols — treated as out of bounds. forum
PCAC vs longevity lore: July 2026 compounding talk reviewed insomnia, not telomere ‘reset.’ Do not read a 503A vote as a longevity approval. trialforum
Cancer data honesty (both directions): Originator-line rodent work sometimes reports lower tumor rates, fewer metastases, or leukemia reduction; some Russian follow-up narratives claimed lower cancer incidence in treated elderly cohorts — not independent Western proof of safety or of risk. trial
Regulatory: Not FDA-approved for anti-aging or any human indication in the US; Russian medicinal history for epithalamin ≠ global approval for Epitalon. trial
Evidence gap: Large modern Western longevity RCTs are absent; most English-language summaries still lean on a single research lineage plus forum charts; no established clinical half-life or target blood level. trial
Not risk-free: “Well tolerated” forum culture and short courses do not equal long-term carcinogenicity packages, drug-interaction matrices, or pharmaceutical-grade PK/PD. trial
Regulatory language note: Secondary summaries of FDA reviewer commentary on telomerase-upregulating peptides have highlighted theoretical “potential to be carcinogenic” concern for chronic use scenarios — this is risk-framing, not a completed human carcinogenicity package either way. trial

Updated: 2026-09-01

Evidence mix Mostly community / anecdote tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.

↑ Back to top

Half-life & effect duration

Timing context & sources⌄

Half-life in the body

Felt duration people report

Other context in this card

What people say 16

Doses people talk about 23

How it may feel 8

Around the dose 5

Cycles people discuss 11

Timing 7

More on what it is 7

Stacks 14

Access talk 6

Labs people mention 3

Storage notes 2

Related 8

Watch for 18

Timing context & sources